Analysts think VERV stock price could increase by 287%
Mar 24, 2025, 11:25 AM
-5.15%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
10 analysts think VERV stock price will increase by 287.34%. The current median analyst target is $21.42 compared to a current stock price of $5.53. The lowest analysts target is $15.15 and the highest analyst target is $33.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
